Daniel Ghinn

Fascinated student of digital health communication. Podcast host. Founder, @CREATION. Always learning.

[Daniel Ghinn @creationdaniel]

If you got access to CREATION Intelligence today, congratulations! And thank you for being part of our launch at #ESMO26.

Here's my first look at today's HCP digital intelligence as ESMO approaches, and guide for you to get started.

There's so much you can do with this, from hearing how HCPs are discussing your trials and products, to learning what really matters to them, to discovering which HCPs are having the greatest impact in the online conversation (you might call them Digital Opinion Leaders).

Try this for yourself, if you got your access today. If you did not apply, it's not too late: https://t.co/eyeMsE9Glr

If you're at ESMO, come and say hello to the https://t.co/ud2cQxMJbM team on stand 1060a (adjacent to Novartis and Boehringer Ingelheim) - we'll be there to help you get started and make the most of the platform during the congress.

[Daniel Ghinn @creationdaniel]

Top HCPs in the #breastcancer conversation right now who are posting on #ESMO26 day 1, based on overall peer impact over the past 12 months:

@ErikaHamilton9
@dr_yakupergun
@PTarantinoMD
@DrRishabhOnco
@stage4kelly
@drsarahsam
@Dr_Oncologista
@Dr_RShatsky

Stop by stand 1060a and try the @CREATION Intelligence app for yourself

[Paolo Tarantino @PTarantinoMD]

🇨🇳HORIZON-Breast06: Trastuzumab rezatecan widely outperformed chemo in endocrine-refractory HR+ MBC (PFS 16.6 vs 6.8 months, HR 0.25, p=0<0.01). Definitely passes the truck test. No significant OS, likely due to crossover of some patients to TOPO1 ADCs. #ESMO26 #ESMOAmbassadors

[Daniel Ghinn @creationdaniel]

During the NATALEE readout, it's the top trending trial in the live HCP conversation at #ESMO26.

For the first time, you can track how HCPs are reacting to trial data as it happens.

Stop by stand 1060a to try it for yourself.

[Daniel Ghinn @creationdaniel]

@NovartisCancer @CREATION This morning's story on NATALEE, which is rising up the trending trials in HCP conversations during #ESMO26

[Daniel Ghinn @creationdaniel]

Right now there's growing anticipation among HCPs for @NovartisCancer NATALEE trial 6-year breast cancer survival results due to be presented at #ESMO26, according to @CREATION Intelligence.

We're tracking the HCP reactions as they happen at ESMO, and if you're in pharma or an HCP, you can too! Get access at https://t.co/eyeMsE98vT

[Daniel Ghinn @creationdaniel]

HCPs anticipate new treatment guidelines in #ovariancancer, says CREATION Intelligence.

HCPs and pharma, get your access during #ESMO26 at https://t.co/JgIO9qIrWe

[Daniel Ghinn @creationdaniel]

@MaverickNY I'll DM you 👍

[Daniel Ghinn @creationdaniel]

If you got access to CREATION Intelligence today, congratulations! And thank you for being part of our launch at #ESMO26.

Here's my first look at today's HCP digital intelligence as ESMO approaches, and guide for you to get started.

There's so much you can do with this, from hearing how HCPs are discussing your trials and products, to learning what really matters to them, to discovering which HCPs are having the greatest impact in the online conversation (you might call them Digital Opinion Leaders).

Try this for yourself, if you got your access today. If you did not apply, it's not too late: https://t.co/eyeMsE9Glr

If you're at ESMO, come and say hello to the https://t.co/ud2cQxMJbM team on stand 1060a (adjacent to Novartis and Boehringer Ingelheim) - we'll be there to help you get started and make the most of the platform during the congress.

[OncoAlert @OncoAlert]

🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁

The abstracts our faculty picked as must-know from Madrid 👇

1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-SCLC
2️⃣ Krascendo 1 (LBA5): divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC
3️⃣ SAFFRON (LBA6): osimertinib + savolitinib in EGFRm MET+ NSCLC post-osimertinib
4️⃣ OptiTROP-Lung04 (LBA67): final OS, sac-TMT vs chemo after EGFR-TKI
5️⃣ OptiTROP-Lung06 (LBA66): sac-TMT + pembro, 1L PD-L1-negative non-squamous NSCLC
6️⃣ PERSEE (2614O): pembro ± chemo, 1L PD-L1 ≥50%
7️⃣ SANOVO (LBA69): savolitinib + osimertinib, 1L EGFRm MET-overexpressed NSCLC
8️⃣ IFCT-2103 DIAL (2618RO): continue pembro vs observation at 6 months
9️⃣ PANKU-Lung01 (LBA71): iza-bren after third-generation EGFR TKI
🔟 SARON (2613O): consolidation radiotherapy in oligometastatic NSCLC

#lcsm #OncoAlert #MedTwitter

Pinging our OncoAlert Lung Cancer Faculty

@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD

@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran

[OncoAlert @OncoAlert]

OncoAlert 4Sight Abstracts to be Presented at #ESMO26
1RO: Final Overall Survival Analysis of postMONARCH: Abemaciclib Plus Fulvestrant After Progression on Prior CDK4/6 Inhibitor in HR+, HER2– Advanced Breast Cancer

@KalinskyKevin
@BianchiniGP
@ErikaHamilton9
@DrSGraff
@drsarahsam
@MuozMateu

🔬 Phase 3, double-blind trial (n=368): abemaciclib or placebo plus fulvestrant in HR+, HER2– ABC after progression on prior CDK4/6i + ET. Final OS analysis.
➡️ Median OS 32.1 vs 24.6 mo; HR 0.80 (0.60–1.06); p=0.1145, statistical significance not reached
➡️ Updated PFS HR 0.78 (0.62–0.99); nominal p=0.0390
➡️ Safety consistent with the established abemaciclib profile; no new signals
✅ Numerically longer median OS, not statistically significant. While absolute PFS benefit was modest, overall evidence supports considering abemaciclib-based treatment after disease progression on prior CDK4/6i + ET. #BreastCancer

🎙️ Kevin Kalinsky
👥 Giampaolo Bianchini · Erika Hamilton · Stephanie Graff · Kyong Hwa Park · Rinath Jeselsohn · Umut Demirci · Miguel Martin · Rachel Layman · Sara Hurvitz · Sarah Sammons · Peter Kaufman · Montserrat Muñoz · Jiun-I Lai · Holly Knoderer · Cynthia Sandoval · Aarti Chawla · Bastien Nguyen · Yanhong Zhou · Elizabeth Ravenberg · Lacey Litchfield · Lillian Smyth · Seth Wander

(4Sight Made from Abstracts publicly available at the ESMO website)

Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista

[ESMO - Eur. Oncology @myESMO]

One week to go until #ESMO26
Share your research or clinical highlights and key takeaways with the #OncologyCommunity.
Use #ESMO26 in your posts to be part of the scientific conversation and connect with colleagues from around the world.

[Daniel Ghinn @creationdaniel]

@Liz_ORiordan Welcome back! What made you change your mind? 🤔

[Daniel Ghinn @creationdaniel]

@Sarah_Moharem @lufthansa I'm so sorry to hear you had this experience after your contribution at ESC

[Hany Ragy @Hragy]

My most important tweet this year?

Dr Pasquale : your chance of being born outside Africa or Asia is 15% , yet all the representation in trials is from countries outside Africa and Asia, the global pharma and device exclude them from trials! #ESCCongress

[Daniel Ghinn @creationdaniel]

I promised yesterday to show you a deep dive into a Digital Opinion Leader profile with LIVE updates today, so I'm keeping that promise!

Here's a look at our #HCM DOL Finder LIVE we're testing at #ESCCongress, which has been capturing excitement today around some key trials being presented.

You'll see the impact that physicians like @MasriAhmadMD , @AndrewJSauer and @drbennisahmed are having in sharing their immersion reflections on new data presented today.

These live updates take the DOL Finder platform to a new level - you no longer need to wait for the next data refresh but can immediately see how doctors are reacting. During medical congress, that can make all the difference to the in-person conversations you have.

[Daniel Ghinn @creationdaniel]

@Hragy It was a pleasure to meet Pr. Soliman at #ESCCongress this afternoon.
@Hragy we had a good chat about the huge impact of your own work especially in sharing scientific information to other physicians on social media

[Daniel Ghinn @creationdaniel]

Cardiologists and other HCPs are posting their reactions to new data and ideas at #ESCCongress, and the @CREATION team is here tracking whose posts are making a big impact in scientific learning.

If you're posting your ideas about the science you're seeing, come find me and I'll show you an analysis of your own peer engagement and impact in #CVRM indications

[Daniel Ghinn @creationdaniel]

At the end of day 1 at #ESCCongress, here's a quick look at the world's most impactful HCPs who have been engaged in the #CVRM digital conversation.

Tomorrow I'll show you what we discover when we dive into one of those profiles.

Top HCPs ranked by global impact so far:
@IhabFathiSulima
@HanCardiomd
@drbennisahmed
@AnastasiaSMihai
@drahmedmohsen85
@Hragy
@Ed_Alania
@Drmahmoudhashe1
@mmamas1973

NB rankings are for overall impact in the scientific digital conversation, not simply volume of posts, measured over the past 12 months of CVRM related digital conversation.

Source: @CREATION DOL Finder LIVE

[Dr Amol Akhade @SuyogCancer]

There is intresting live debate going on X amongst people whom I admire ( on X and in real world both ) @oncology_bg @Dr_R_Kurzrock @dr_yakupergun
ORR Vs OS
I could not resist the temptation to make this infographic to show both sides on 1 page for benifit of audience on X .

[Daniel Ghinn @creationdaniel]

Research shows the most peer-trusted healthcare professional voices shaping NSCLC scientific learning online during the last three years of ASCO.

@CREATION's unique HCP Peer Impact metric, an algorithm based on how often other HCPs mention a particular HCP within a specific conversation (in this case, posts about lung cancer during ASCO medical congress), is a powerful way to identify which oncologists or other HCPs are most trusted by their online peers.

You'll notice that the most peer-trusted HCPs are not necessarily the noisiest or most-prolific posters, but they certainly play their part.

Ones to watch for #ASCO26:

#1 @StephenVLiu
#2 @HHorinouchi
#3 @CharuAggarwalMD
#4 @RManochakian
#5 @DrJNaidoo

#ASCO23 #ASCO24 #ASCO25 #ASCO26